Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR3824 plus SP2086 vs placebo plus SP2086 in type 2 diabetes
CTR20180547Phase 2Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of henagliflozin, linagliptin in type 2 diabetes mellitus (T2DM), sponsored by Hengrui Therapeutics. Started Apr 2018; status: completed.
02
Drugs
henagliflozinlinagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20180547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180547.